Best Stem cell therapy for Parkinson's disease Clinics and Prices in Republic of Korea for Australians

Stem cell therapy for Parkinson's disease is approved in South Korea. It is available under the Advanced Regenerative Bio Act for severe neurological conditions. Treatments include TED-A9 dopaminergic precursor cells and arterial infusions. They are available at authorised Ministry of Food and Drug Safety (MFDS) institutions in Seoul and Cheonan.

• Regulatory framework: The 2025 Act allows specialised treatments for patients outside traditional clinical trials.
• Specialised delivery: RE:YOUTH clinic provides arterial stem cell therapy to target brain tissue directly.
• Clinical results: High-dose TED-A9 therapy showed a 15.5-point motor score improvement in one year.
• Specialists: Dr Phil Hyu Lee at Severance Hospital brings 20+ years of neurological experience.

Bookimed Expert Insight: Many clinics offer IV infusions. However, RE:YOUTH in Cheonan is the only Korean centre providing direct arterial infusion. This delivery method bypasses the blood-brain barrier. This clinic limits intake to 2 daily patients. Therefore, booking 4–6 weeks ahead is essential for international arrivals.

Patient Consensus: Recent legislative changes in South Korea now allow access to dopaminergic cell therapy. This includes those not in trials. Patients report significant motor improvements and better walking stability. These benefits follow treatment with the specific precursor cells.

Stem cell therapy for Parkinson's disease in South Korea is generally safe when performed at KOIHA-accredited institutions regulated under the Advanced Regenerative Bio Act. While experimental, recent trials show no major complications like tumour formation. However, risks include surgical infection, immune rejection, or unproven long-term efficacy.

• Government oversight: The Ministry of Food and Drug Safety (MFDS) regulates 112 designated medical institutions.
• Delivery techniques: Specialised clinics like RE:YOUTH use arterial infusion to bypass lungs and reach the brain.
• Surgical risks: Direct dopaminergic precursor implantation requires two brain surgeries, carrying standard neurosurgical risks.
• Credentialed specialists: Doctors like Phil Hyu Lee at Severance Hospital bring 20+ years of neurology experience.

Bookimed Expert Insight: South Korea offers a rare arterial delivery method not commonly available elsewhere. RE:YOUTH clinic limits intake to two patients daily. This focus on VIP-level care often results in more thorough pre-surgical screening compared to high-volume centres.

Patient Consensus: Patients report motor symptom improvements in Korea. However, they stress that results vary since the therapy is experimental. They suggest focusing on officially registered trials and avoiding providers who promise a guaranteed cure.

South Korea offers stem cell therapy for Parkinson's disease focusing on replacing dopamine-producing neurons. Key benefits include high-purity cell generation, targeted arterial delivery, and regulatory oversight under the Advanced Regenerative Bio Act. Clinical trials show significant motor improvement and potential long-term disease modification.

• Purity levels: Researchers achieve 99.57% purity in dopaminergic nerve cells.
• Targeted delivery: RE:YOUTH clinic uses arterial infusion to bypass organs.
• Motor improvement: Patient data shows up to 15.5-point MDS-UPDRS scale gains.
• Symptom relief: Early trials report complete resolution of gait freezing.
• Specialist expertise: Dr Phil Hyu Lee has 20+ years of neuro-regeneration experience.

Bookimed Expert Insight: While many countries offer basic intravenous stem cells, South Korea specialises in TED-A9 dopaminergic precursor cells. Data shows this specific approach triggers gradual brain reinnervation over 18–24 months. Clinics like RE:YOUTH limit intake to 2 patients daily to maintain these strict delivery protocols.

Patient Consensus: Patients report disease stabilisation and significant non-motor symptom relief in South Korea. They highlight the importance of planning for a long-term recovery. This is because brain reinnervation is gradual.

South Korean clinics use allogeneic pluripotent-derived dopaminergic precursor cells, specifically TED-A9. They also use autologous mesenchymal stem cells from fat tissue. Delivery methods include stereotactic neurosurgical injection directly into the brain. Another method is targeted arterial infusion to bypass systemic filters like the lungs for maximum effect.

• TED-A9 cells: These donor-derived dopaminergic precursor cells aim to replace lost neurons.
• Autologous MSCs: Patients use their own fat or skin cells via IV infusion.
• Stereotactic injection: Surgeons deliver TED-A9 directly into the brain during neurosurgery.
• Targeted arterial delivery: This specialised technique directs cells towards the brain via arteries.
• Government regulation: All treatments must comply with the Advanced Regenerative Bio Act.

Bookimed Expert Insight: Many clinics offer simple IV infusions. However, the most effective Korean protocols for motor symptoms require surgical brain injection. Specialists like Dr Phil Hyu Lee at Severance Hospital focus on these targeted applications. Recent data shows high-dose injections can improve motor symptoms by over 15 points within one year.

Patient Consensus: Patients mention that effective therapy involving TED-A9 requires surgery rather than a simple drip. Travellers to South Korea note that motor improvements and gait resolution may take three years.

South Korea is a global hub for neurodegenerative research. Severance Hospital in Seoul leads major trials using embryonic stem cell-derived neurons. Other prominent institutions include CHA University and Seoul National University Hospital. These focus on safety and multidisciplinary care for neurological conditions.

• Severance Hospital: Conducts Phase 1/2a trials using embryonic stem cell-derived neurons for Parkinson's.
• Dr Phil Hyu Lee: Specialist at Severance with 20+ years of experience in neurology research.
• Arterial infusion: RE:YOUTH Clinic specialises in targeted arterial delivery of cells to cerebral arteries.
• KOIHA accreditation: Leading Korean centres must meet these international quality and safety benchmarks.

Bookimed Expert Insight: While university hospitals like Severance lead research, specialised centres like RE:YOUTH Clinic in Cheonan take a different approach. They limit intake to 2 patients daily. This means patients receive VIP-level attention and highly customised plans for direct arterial infusion treatments.

Patient Consensus: Patients value the multidisciplinary approach in Seoul for complex cases. Many focus on Severance's historical trial successes and consult Australian neurologists for safety advice.